# US 2008/0187590 A1 · Oral Dosage Form

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187590 A1
- Document ID: US20080187590A1
- Status: Published application
- Kind: A1
- Application number: 11/916,460
- Filed: 2006-06-07
- Published: 2008-08-07
- Earliest claimed: 2005-06-08
- Inventors: Kari Vahervuo
- Web page: https://patentgrep.com/patent/US20080187590A1

## CPC

- A61K 31/277: having a ring, e.g. verapamil
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/2853: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 31/195: having an amino group
- A61K 31/275: Nitriles; Isonitriles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/16: Anti-Parkinson drugs
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An oral dosage form of entacapone and methods for the preparation thereof are provided.

## Claims

### Claim 1

An oral dosage form comprising a pharmacologically effective amount of entacapone as the sole drug substance, wherein the amount of entacapone in a portion of the oral dosage form is from 35% to 99% by weight of the portion.

### Claim 2 (depends on 1)

The oral dosage form according to claim 1, wherein the amount of entacapone is from 50% to 65% by weight of the portion.

### Claim 3 (depends on 1)

The oral dosage form according to claim 1, wherein entacapone is in particulate form and at least 90% of entacapone particles have a diameter less than 55 μm.

### Claim 4 (depends on 1)

The oral dosage form according to claim 1, wherein entacapone is in particulate form and at least 90% of entacapone particles have a diameter less than 35 μm.

### Claim 5 (depends on 1)

The oral dosage form according to claim 1, wherein entacapone is in particulate form and not more than 20% of entacapone particles have a diameter less than 2 μm.

### Claim 6 (depends on 1)

The oral dosage form according to claim 1, further comprising at least one binder.

### Claim 7 (depends on 6)

The oral dosage form according to claim 6, wherein the at least one binder is chosen from povidone, hypromellose, hydroxypropyl cellulose, methylcellulose, and gelatine.

### Claim 8 (depends on 6)

The oral dosage form according to claim 6, wherein the at least one binder is povidone, and the amount of povidone is from 0.5% to 8% by weight of the portion.

### Claim 9 (depends on 1)

The oral dosage form according to claim 1, further comprising at least one disintegrant.

### Claim 10 (depends on 9)

The oral dosage form according to claim 9, wherein the at least one disintegrant is chosen from croscarmellose sodium, crospovidone, low substituted hydroxypropyl cellulose, microcrystalline cellulose, and sodium starch glycolate.

### Claim 11 (depends on 10)

The oral dosage form according to claim 10, wherein the at least one disintegrant is croscarmellose sodium, and the amount of croscarmellose sodium is from 18% to 27% by weight of the portion.

### Claim 12 (depends on 11)

The oral dosage form according to claim 11, further comprising microcrystalline cellulose, and the proportion of croscarmellose sodium to microcrystalline cellulose is from 40:60 to 80:20 by weight of the portion.

### Claim 13 (depends on 1)

The oral dosage form according to claim 1, wherein at least 50% of entacapone is released within the first 30 minutes from the dosage form in a dissolution test (Apparatus 2 (USP), paddles at 50 rpm, pH 5.5).

### Claim 14 (depends on 1)

The oral dosage form according to claim 1, wherein at least 60% of entacapone is released within the first 45 minutes from the dosage form in a dissolution test (Apparatus 2 (USP), paddles at 50 rpm, pH 5.5).

### Claim 15 (depends on 1)

The oral dosage form according to claim 1, wherein the oral dosage form is a tablet.

### Claim 16 (depends on 15)

The tablet according to claim 15 comprising magnesium stearate, wherein the amount of magnesium stearate is from 0.1% to 3% by weight of the portion.

### Claim 17 (depends on 15)

The tablet according to claim 15, wherein the tablet is coated, and the amount of the tablet coating is from 0.5% to 10% by weight of the core of the tablet.

### Claim 18 (depends on 15)

The tablet according to claim 15, comprising 200 mg of entacapone and has the following characteristics:
length from 11 mm to 16 mm
width from 4 mm to 9 mm, and
height from 4 mm to 7 mm.

### Claim 19 (depends on 1)

A kit comprising an oral dosage form according to claim 1, levodopa, a dopa decarboxylase inhibitor, and optionally at least one other drug substance.

### Claim 20

A method for the preparation of a core tablet comprising
(i) preparing a mixture of entacapone as the sole drug substance with at least one binder and optionally one or more other excipients, and granulating the mixture with a granulating liquids
or granulating entacapone as the sole drug substance with at least one optional other excipient with a granulating liquid comprising at least one binder,
or by melt granulation;
(ii) drying or cooling, and optionally screening the granules of step (i), optionally bringing the granules into contact with at least one extragranular excipient; and
(iii) compressing the granules and the at least one optional extragranular excipient into a core tablet.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the at least one binder is chosen from povidone, hypromellose, hydroxypropyl cellulose, methylcellulose, and gelatine.

### Claim 22 (depends on 20)

The method according to claim 20, wherein the granulating liquid is water, a lower alcohol, or a mixture thereof.

### Claim 23 (depends on 20)

The method according to claim 20, comprising granulating entacapone in the presence of an excipient, wherein the excipient is at least one disintegrant.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the at least one disintegrant is chosen from croscarmellose sodium, crospovidone, low substituted hydroxypropyl cellulose, microcrystalline cellulose and sodium starch glycolate.

### Claim 25 (depends on 23)

The method according to claim 23, wherein the granulation liquid is water, the at least one disintegrant is croscarmellose sodium, and the amount of water added during the granulation is from 50% to 120% by weight of the dry weight of the granulation mass, or the at least one disintegrant is L-HPC and the amount of water added during granulation is from 30% to 100% by weight of the dry weight of the granulation mass.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the at least one disintegrant is croscarmellose sodium and the amount of water added during the granulation is from 70% to 100% by weight of the dry weight of the granulation mass.

### Claim 27 (depends on 20)

The method according to claim 20, wherein the core tablet is further coated.

### Claim 28 (depends on 20)

A tablet prepared according to the method of claim 20.

### Claim 29 (depends on 20)

A kit comprising
the tablet prepared according to claim 20 levodopa,
a dopa decarboxylase inhibitor, and
optionally at least one other drug substance.

### Claim 30

A method for the preparation of granules of entacapone comprising
(i) preparing a mixture of entacapone as the sole drug substance with a binder and optionally at least one other excipient, and granulating the mixture with a granulating liquid,
or granulating entacapone as the sole drug substance with at least one optional other excipient with a granulating liquid comprising a binder, or by melt granulation;
(ii) drying or cooling, and optionally screening the granules of step (i).

### Claim 31 (depends on 30)

Granules prepared according to the method of claim 30.

### Claim at position 32

32-33. (canceled)

### Claim 34 (depends on 30)

A method for the preparation of a granule mixture of entacapone comprising bringing the granules made according to claim 30 into contact with at least one extragranular excipient.

### Claim 35 (depends on 34)

A granule mixture prepared according to the method of claim 34.

### Claim 36

A method for the preparation of a capsule of entacapone comprising
(i) preparing a mixture of entacapone as the sole drug substance with a binder and optionally at least one other excipient, and granulating the mixture with a granulating liquid,
or granulating entacapone as the sole drug substance with at least one optional other excipient with a granulating liquid comprising a binder, or by melt granulation;
(ii) drying or cooling, and optionally screening the granules of step (i), optionally bringing the granules into contact with at least one extragranular excipient; and
(iii) filling the granules and at least one optional extragranular excipient into a suitable capsule.

### Claim 37 (depends on 36)

A capsule prepared according to the method of claim 36.

### Claim 38 (depends on 36)

A kit comprising
the capsule prepared according to claim 36 levodopa,
a dopa decarboxylase inhibitor, and
optionally at least one other drug substance.

### Claim 39 (depends on 1)

A method for inhibiting the COMT enzyme in a mammal, comprising administering to the mammal in need of the inhibition an effective amount of the oral dosage form of claim 1.

### Claim 40 (depends on 1)

A method for treating Parkinson's disease in a mammal, comprising administering to the mammal in need of the treatment an effective amount of the oral dosage form of claim 1.

### Claim 41 (depends on 1)

A method for treating restless legs syndrome, comprising administering to the mammal in need of the treatment an effective amount of the oral dosage form of claim 1.

### Claim 42 (depends on 30)

A dosage form comprising the granules prepared according to the method of claim 30.

### Claim 43 (depends on 34)

A dosage form comprising the granule mixture prepared according to the method of claim 34.
